Vanguard Group Inc. Boosts Stock Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Vanguard Group Inc. raised its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 0.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,968,980 shares of the medical technology company's stock after buying an additional 47,797 shares during the period. Vanguard Group Inc. owned 4.21% of Alphatec worth $54,795,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ATEC. R Squared Ltd bought a new stake in shares of Alphatec during the 4th quarter worth approximately $29,000. Nisa Investment Advisors LLC grew its position in shares of Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock valued at $43,000 after acquiring an additional 4,234 shares during the period. Newton One Investments LLC acquired a new position in shares of Alphatec during the 4th quarter worth about $50,000. XTX Topco Ltd bought a new position in Alphatec during the third quarter worth about $69,000. Finally, AlphaQuest LLC bought a new stake in Alphatec in the 4th quarter valued at $80,000. 66.35% of the stock is owned by institutional investors.

Alphatec Price Performance

Shares of Alphatec stock traded up $0.02 during trading on Thursday, reaching $10.25. 194,977 shares of the company's stock were exchanged, compared to its average volume of 2,107,138. The company has a market cap of $1.48 billion, a P/E ratio of -8.01 and a beta of 1.20. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The firm's 50-day moving average price is $10.38 and its 200 day moving average price is $9.38. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $13.79.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The firm had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. As a group, research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Insider Transactions at Alphatec

In related news, EVP David Sponsel sold 33,732 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total value of $365,317.56. Following the sale, the executive vice president now directly owns 668,977 shares in the company, valued at $7,245,020.91. This represents a 4.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Patrick Miles sold 6,687 shares of Alphatec stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00. Following the transaction, the chief executive officer now directly owns 5,501,715 shares of the company's stock, valued at $66,020,580. This represents a 0.12 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 278,800 shares of company stock worth $3,201,469. Company insiders own 22.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ATEC shares. Barclays upped their target price on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research report on Monday. Needham & Company LLC reissued a "buy" rating and set a $16.00 target price on shares of Alphatec in a report on Thursday, February 27th. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Finally, Piper Sandler lifted their price objective on shares of Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Alphatec has an average rating of "Moderate Buy" and an average target price of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.